## Rationale for Correct Answer **Key Point:** Loop diuretics are NOT first-line antihypertensive agents in CKD and are reserved for volume overload or advanced renal disease. They do not slow CKD progression and carry risk of electrolyte disturbance and ototoxicity. ## Evidence-Based CKD Management ### Interventions That SLOW Progression | Intervention | Evidence | Mechanism | | --- | --- | --- | | ACE-I / ARB | Strong (KDIGO) | Reduces intraglomerular pressure, reduces proteinuria | | SGLT2 inhibitor | Strong (CREDENCE, DAPA-CKD) | Cardio-renal protection independent of glucose control | | BP target <120 mmHg | Moderate (SPRINT) | Reduces cardiovascular events and slows GFR decline | | Loop diuretic | NOT for progression | Used only for volume management, no renoprotective benefit | ### Why Loop Diuretics Are NOT First-Line 1. **No renoprotective effect** — they do not reduce proteinuria or slow GFR decline 2. **Adverse effects in CKD:** - Electrolyte derangement (hypokalemia, hyponatremia) - Ototoxicity (especially with high doses) - Reflex activation of RAAS and SNS 3. **Indication:** Reserved for volume overload (pulmonary edema, peripheral edema) or advanced CKD (Stage 4–5) **High-Yield:** ACE-I/ARB and SGLT2 inhibitors are the cornerstones of CKD-slowing therapy; loop diuretics are symptom-relief agents only. **Clinical Pearl:** In non-diabetic CKD, SGLT2 inhibitors (e.g., dapagliflozin) have proven benefit even without diabetes, as shown in DAPA-CKD trial. ## KDIGO 2021 Guideline Hierarchy ```mermaid flowchart TD A[CKD Stage 3-4 with Proteinuria]:::outcome --> B{Diabetes present?}:::decision B -->|Yes| C[ACE-I/ARB + SGLT2i]:::action B -->|No| D[ACE-I/ARB if proteinuria present]:::action D --> E[Add SGLT2i for cardio-renal benefit]:::action C --> F[Target BP <120 mmHg systolic]:::action E --> F F --> G[Loop diuretic only if volume overload]:::action ``` [cite:KDIGO 2021 CKD Management Guidelines]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.